Evidence map›Paper›PMID 27427455›Full record

ReviewLancet (London, England)2016

The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.

Frederick L Altice, Lyuba Azbel, Jack Stone, Ellen Brooks-Pollock, Pavlo Smyrnov, Sergii Dvoriak, Faye S Taxman, Nabila El-Bassel, Natasha K Martin, Robert Booth and 3 more

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Lancet (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03537196 (Towards HCV Elimination), which is not on this map. Cited by 156 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed, 11 pooled it
23.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03537196 phase4completednot on this mapstarted 2018, after this paper: background citation

Towards HCV Elimination: Evaluation of an Integrated Model of HCV Care Targeting People Who Inject Drugs in Hai Phong, Vietnam

TypeinterventionalSponsorANRS, Emerging Infectious DiseasesRan2018 to 2022Enrolled979ConditionsHepatitis C, Drug Use, Viral Hepatitis CArmsSofosbuvir 400 mg and Daclatasvir 60 mg, Sofosbuvir 400 mg and Daclatasvir 90 mg, Ribavirin, Sofosbuvir and Daclatasvir for 24 weeks
3 · Its place in the literature

Who cites it

156 citing papers in PubMed, 11 syntheses or guidelines pooled it, 279 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2018
    Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

96 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 5 countries.

Frederick L AlticeSchool of Medicine and School Public Health, Yale University, New Haven, CT, USA. Electronic address: frederick.altice@yale.edu.
Lyuba AzbelPublic Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.
Jack StoneSchool of Social and Community Medicine, Bristol University, Bristol, UK.
Ellen Brooks-PollockSchool of Social and Community Medicine, Bristol University, Bristol, UK.
Pavlo SmyrnovICF International Alliance for Public Health, Kiev, Ukraine.
Sergii DvoriakUkrainian Institute on Public Health Policy, Kiev, Ukraine.
Faye S TaxmanDepartment of Criminology, Law and Society, George Mason University, Fairfax, VA, USA.
Nabila El-BasselSchool of Social Work, Columbia University, New York, NY, USA.
Natasha K MartinSchool of Social and Community Medicine, Bristol University, Bristol, UK; Division of Global Public Health, University of California San Diego, San Diego, CA, USA.
Robert BoothDepartment of Psychiatry, University of Colorado, Denver, CO, USA.
Heino StöverInstitute of Addiction Research, Frankfurt University of Applied Sciences, Frankfurt, Germany.
Kate DolanNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia.
Peter VickermanSchool of Social and Community Medicine, Bristol University, Bristol, UK.
University of Bristol · GBAlliance for Public Health · UAColumbia University · USFrankfurt University of Applied Sciences · DEGeorge Mason University · USLondon School of Hygiene & Tropical Medicine · GBUkrainian Institute of Public Health Policy · UAUniversity of Colorado Denver · USUNSW Sydney · AUYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SONIA JAIN · 1994 to 2026
$78.4M
Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
Prison Interventions and HIV Prevention CollaborationR01DA029910 · NIDA · YALE UNIVERSITY · PI FREDERICK LEWIS ALTICE · 2010 to 2026
$7.9M
Expanding Medication Assisted Therapy in Ukraine (ExMAT)R01DA033679 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2012 to 2021
$6.4M
HIV, Buprenorphine, and the Criminal Justice SystemR01DA030768 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2010 to 2015
$4.0M
In-person vs. Computer Interventions to Increase Probation ComplianceR01DA029010 · NIDA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI TAXMAN, FAYE S, WALTERS, SCOTT T · 2011 to 2016
$3.1M
Intervention of HIV, Drug Use and the Criminal Justice System in MalaysiaR01DA025943 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2008 to 2012
$2.7M
Peer Leaders as HIV Risk Reduction Change Agents Among IDUs in UkraineR01DA026739 · NIDA · UNIVERSITY OF COLORADO DENVER · PI BOOTH, ROBERT EDWIN · 2010 to 2014
$2.4M
Enhancing Health Outcomes Among HIV+ Substance AbusersK24DA017072 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2003 to 2012
$1.5M
Modeling Structural HIV Determinants in Substance Users and related populationsR01DA037773 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARTIN, NATASHA, STRATHDEE, STEFFANIE A. · 2015 to 2017
$1.4M
Department of Health PDF-2011-04-049FIC NIH HHS D43 TW010540NCATS NIH HHS UL1 TR001863NIAID NIH HHS P30 AI036214NIDA NIH HHS K24 DA017072NIDA NIH HHS R01 DA025943NIDA NIH HHS R01 DA026739NIDA NIH HHS R01 DA029010NIDA NIH HHS R01 DA029910NIDA NIH HHS R01 DA030768NIDA NIH HHS R01 DA033679NIDA NIH HHS R01 DA037773
6 · The paper itself

Abstract

Despite global reductions in HIV incidence and mortality, the 15 UNAIDS-designated countries of Eastern Europe and Central Asia (EECA) that gained independence from the Soviet Union in 1991 constitute the only region where both continue to rise. HIV transmission in EECA is fuelled primarily by injection of opioids, with harsh criminalisation of drug use that has resulted in extraordinarily high levels of incarceration. Consequently, people who inject drugs, including those with HIV, hepatitis C virus, and tuberculosis, are concentrated within prisons. Evidence-based primary and secondary prevention of HIV using opioid agonist therapies such as methadone and buprenorphine is available in prisons in only a handful of EECA countries (methadone or buprenorphine in five countries and needle and syringe programmes in three countries), with none of them meeting recommended coverage levels. Similarly, antiretroviral therapy coverage, especially among people who inject drugs, is markedly under-scaled. Russia completely bans opioid agonist therapies and does not support needle and syringe programmes-with neither available in prisons-despite the country's high incarceration rate and having the largest burden of people with HIV who inject drugs in the region. Mathematical modelling for Ukraine suggests that high levels of incarceration in EECA countries facilitate HIV transmission among people who inject drugs, with 28-55% of all new HIV infections over the next 15 years predicted to be attributable to heightened HIV transmission risk among currently or previously incarcerated people who inject drugs. Scaling up of opioid agonist therapies within prisons and maintaining treatment after release would yield the greatest HIV transmission reduction in people who inject drugs. Additional analyses also suggest that at least 6% of all incident tuberculosis cases, and 75% of incident tuberculosis cases in people who inject drugs are due to incarceration. Interventions that reduce incarceration itself and effectively intervene with prisoners to screen, diagnose, and treat addiction and HIV, hepatitis C virus, and tuberculosis are urgently needed to stem the multiple overlapping epidemics concentrated in prisons.

Indexed as

Anti-HIV AgentsAntitubercular AgentsAntiviral AgentsAsia, CentralCrimeEurope, EasternHepatitis CHIV InfectionsHumansIncidenceNeedle-Exchange ProgramsOpiate Substitution TreatmentPrisonersPrisonsRiskRisk FactorsAnti-HIV AgentsAntitubercular AgentsAntiviral Agents

Identifiers

PMID27427455
PMCPMC5087988
OpenAlexW2469883028

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.